Serotonin and schizophrenia: A review

Drugs of Today

Volumn 32, Issue 2, 1996, Pages 171-185

  Abi Dargham, Anissa ^a   Laruelle, Marc ^b   Charney, Dennis ^b   Krystal, John ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DOPAMINE 2 RECEPTOR; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

AUTOPSY; BRAIN REGION; CEREBROSPINAL FLUID; HUMAN; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA;

EID: 0030010518     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Gaddum, J.H. Drugs antagonistic to 5-hydroxytryptamine. In: Ciba Foundation Symposium on Hypertension. Wolstenholme, G.W. (Ed.). Little Brown & Co.: Boston 1954, 75-7.
2. Wooley, D.W., Shaw, E. A biological and pharmacological suggestion about certain mental disorder. Proc Natl Acad Sci USA 1954, 40: 228-31.
3. Snyder, S.H. Catecholamines in the brain as mediator of amphetamine psychosis. Arch Gen Psychiatry 1972, 27: 169-79.
4. Kane, J., Honigfeld, G., Singer, J., Meltzer, H.Y. for the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988, 45: 789-96.
5. Meltzer, H.Y. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bull 1991, 17: 263-86.
6. Seeman, P. Atypical neuroleptics: Role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiat Scand 1990, 82: 14-20.
7. Marder, S.R., Meibach, R.C. Risperidone in the treatment of schizophrenia. Amer J Psychiatry 1994, 151: 825-35.
8. Chouinard, G., Jones, B., Remington, G. et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993, 13: 25-40.
9. Dahlström, A., Fuxe, K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1964, 62: 1-55.
10. Azmitia, E.C., Segal, M. Autoradiographic analysis of the differential ascending projection of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978, 179: 641-68.
11. Steinbusch, H.W.M. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminal. Neuroscience 1981, 6: 557-618.
12. Moore, A., Halaris, A. Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat. J Comp Neurol 1975, 164: 171-84.
13. Geyer, M., Puerto, A., Dawsey, W., Knapp, S., Bullard, W., Mandell, A. Histologic and enzymatic studies of the mesolimbic and mesostriatal serotonergic pathways. Brain Res 1976, 106: 241-56.
14. Herve, D., Pickel, V.M., Joh, T.H. Serotonin axon terminals in the ventral tegumental area of the rat: Fine structure and synaptic input to dopaminergic neurons. Brain Res 1987, 435: 71-83.
15. Dray, A., Gonye, T., Oakley, N., Tanner, T. Evidence of the existence of a raphe projection to the substantia nigra in rat. Brain Res 1976, 113: 45-57.
16. Dray, A., Davies, J., Oakley, N.R., Tongroach, P., Vellucci, S. The dorsal and medial raphe projections to the substantia nigra in the rat: Electrophysiological, biochemical and behavioural observations. Brain Res 1978, 151: 431-42.
17. Fibiger, H.C., Miller, J.J. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 1977, 2: 975-87.
18. Phillipson, O.T. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: A horseradish peroxidase study in the rat J Comp Neurol 1979, 187: 117-44.
19. Wright, D.E., Seroogy, K.B., Lundgren, K.H., Davis, B.M., Jennes, L. Comparative localization of serotonin, (1A), (1C) and (2) receptor subtype mRNAs in rat brain. J Comp Neurol 1995, 351: 357-73.
20. 3H]-LY278584 binding sites in human brain. J Neurochem 1992, 60: 730-3.
21. Shen, Y., Monsma, F. Jr., Metcalf, M.A., Jose, P.A., Hamblin, M.W., Sibley, D.R. Molecular cloning and expression of a 5-hydroxytryptamine-7 serotonin receptor subtype. J Biol Chem 1993, 268: 18200-4.
22. Roth, B.L., Craigo, S.C., Choudhary, M.S. et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994, 268: 1403-10.
23. Monsma, F. Jr., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993, 43: 320-7.
24. Rinkel, M., Hyde, R., Solomon, H., Hoagland, H. Experimental psychiatry II: Clinical and physicochemical observations in experimental psychosis. Amer J Psychiatry 1955, 111: 881-95.
25. Hollister, L.E. Drug-induced psychoses and schizophrenic reactions: A critical comparison. Ann NY Acad Sci 1962, 96: 80-8.
26. Fishman, L. Dreams, hallucinogenic drug states and schizophrenia: A psychological and biological comparison. Schizophrenia Bull 1983, 9: 73-94.
27. Aghajanian, G.K. Serotonin and the action of LSD in the brain. Psychiat Ann 1994, 24: 137-41.
28. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984, 35: 2505-11.
29. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 1988, 94: 231-316.
30. Stahl, S.M., Wets, K. Indolamines and schizophrenia. In: Handbook of Schizophrenia, Vol. 2: Neurochemistry and Neuropharmacology of Schizophrenia. Henn, F.A., DeLisi, L.E. (Eds.). Elsevier: Amsterdam 1987, 257-96.
31. Bleich, A., Brown, S-L., Kahn, R., van Praag, M. The role of serotonin in schizophrenia. Schizophrenia Bull 1988, 14: 297-315.
32. Ashcroft, G.W., Crawford, T.B.B., Eccleston, D. et al. 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet 1966, ii: 1049-52.
33. Bowers, M.B. Jr., Heninger, G.R., Gerbode, F. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients. Int J Neuropharmacol 1969, 8: 255-62.
34. Gomes, U.C.R., Shanley, B.C., Potgieter, L., Roux, J.T. Noradrenergic overactivity in schizophrenia: Evidence based on cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. Brit J Psychiatry 1980, 137: 346-51.
35. Wode-Helgodt, B., Fyro, B., Gillberg, B., Sedvall, G. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluids in psychotic patients. Acta Psychiat Scand 1977; 56:129-?
36. Persson, T., Roos, B.E. Acid metabolites from monoamines in cerebrospinal fluid of chronic schizophrenics. Brit J Psychiatry 1969, 115: 95.
37. Rimon, R., Roos, B.E., Rakkolainen, V., Alanen, Y. The content of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia. J Psychosom Res 1971, 15: 375-8.
38. Post, R.M., Fink, E., Carpenter, W.T., Goodwin, F.K. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 1975, 32: 1063-9.
39. Bowers, M.B. Jr. Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry 1974, 31: 50-4.
40. Nybäck, H., Berggren, B.M., Hindmarsh, T., Sedvall, G., Wiesel, F.A. Cerebroventricular size and monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res 1983, 9: 301-8.
41. Potkin, S., Weinberger, D.R., Linnoila, M., Wyatt, R.J. Low CSF 5-hydroxyindoleacetic acid in schizophrenic brains with enlarged ventricles. Amer J Psychiatry 1983, 140: 21-5.
42. Losonczy, M.F., Song, I.S., Mohs, R.C. et al. Correlates of lateral ventricular size in chronic schizophrenia, II: Biological measures. Amer J Psychiatry 1986, 143: 1113-8.
43. Jennings, W.S., Schultz, S.C., Narasimhachar, N., Hamer, R.M., Friedel, R.O. Brain ventricular size and CSF monoamine metabolite in an adolescent inpatient population. Psychiatry Res 1984, 16: 87-94.
44. Pickar, D., Roy, A., Brieer, A. et al. Suicide and aggression in schizophrenia. Neurobiologic correlates. In: Psychobiology of Suicidal Behavior. Mann, J.J., Stanley, M. (Eds.). Ann NY Acad Sci 1986, 189-96.
45. Weinberger, D.R., Berman, K.F., Illowsky, B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988, 45: 609-15.
46. Kahn, R.S., Davidson, M., Knott, P., Stern, R.G., Apter, S., Davis, K.L. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment Arch Gen Psychiatry 1993, 50: 599-605.
47. Winblad, B., Bucht, G., Gottfries, C.G., Roos, B.E. Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiat Scand 1979, 60: 17-28.
48. Crow, T.J., Baker, H.F., Cross, A.J. et al. Monoamine mechanisms in chronic schizophrenia: Post-mortem neurochemical findings. Brit J Psychiatry 1979, 134: 249-56.
49. Farley, I.J., Shannak, K.S., Hornykiewicz, O. Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased receptor sensitivity. In: Receptor for Neurotransmitters and Peptides. Pepeu, G., Kuhar, M.J. Enna, S.J. (Eds.). Raven Press: New York 1980, 427-33.
50. Laruelle, M., Abi-Dargham, A., Casanova, M.F., Toti, R., Weinberger, D.R., Kleinman, J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: A postmortem study. Arch Gen Psychiatry 1993, 50: 810-8.
51. Joyce, J.N., Shane, A., Lexow, N., Winokur, A., Casanova, M.F., Kleinman, J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993, 8: 315-36.
52. Ohuoha, D.C., Hyde, T.M., Herman, M.M., Kleinman, J.E. Prefrontal serotonin receptor subtypes in schizophrenia and nonpsychotic suicides: An autoradiographic study. Arch Gen Psychiat, in press.
53. Dean, B., Opeskin, K., Pavey, G. et al. [H-3]Paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem 1995, 64: 1197-202.
54. 3H]spiperidol. Mol Pharmacol 1979, 16: 687-99.
55. Bennett, J.P., Enna, S.J., Bylund, D.B., Gillin, J.C., Wyatt, R.J., Snyder, S.H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979, 36: 927-34.
56. Whitaker, P.M., Crow, T.J., Ferrier, I.N. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 1981, 38: 278-80.
57. 2 receptors in chronic schizophrenics. Biol Psychiatry 1986, 21: 1407-14.
58. 2) receptor binding in frontal cortex of schizophrenic patients. J Neural Transm 1991, 85: 19-29.
59. 2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm 1983, Suppl. 18): 273-7.
60. 2-serotonergic receptors. Life Sci 1983; 33: 2527-2533.
61. Andree, T.H., Mikini, M., Yong, C.Y., Koenig, J.I., Meltzer, H.Y. Differential effects of subchronic treatment with various neuroleptic agents on serotonin-2 receptors in rat cerebral cortex. J Neurochem 1986, 46: 191-7.
62. 2 receptors in rat brain following chronic receptor blockade. J Receptor Res 1987, 7: 223-39.
63. Leysen, J., Niemegeers, C., Tollenaere, J., Laduron, P. Serotonergic component of neuroleptic receptors. Nature 1978, 272: 168-71.
64. 3H-ligand for serotonin-2 receptor binding sites: Binding properties, brain distribution and functional role. Mol Pharmacol 1982, 21: 301-14.
65. 2 receptors of normal human brain in vitro. Eur J Pharmacol 1987, 143: 279-82.
66. 2 and β-adrenergic receptors in the brains of suicide victims. Arch Gen Psychiatry 1990, 47: 1038-47.
67. 2 binding sites in the frontal cortex of suicide victims. Amer J Psychiatry 1989, 146: 730-6.
68. 2 sites in cortex and amygdala. Brain Res 1993, 614: 37-44.
69. Mann, J.J., Stanley, M., McBride, P.A., McEwen, B.S. Increased serotonin-2 and beta receptor in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986, 43: 954-59.
70. Stanley, M., Mann, J.J. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983, ii: 214-6.
71. 2 receptor binding sites in depressed suicide victims. Brain Res 1988, 443: 272-80.
72. Owen, F., Chambers, D.R., Cooper, S.J. et al. Serotonergic mechanisms in brain of suicide victims. Brain Res 1986, 362: 185-8.
73. 2 receptors in suicide victims: Violence of death, depression and effects of antidepressant treatment. Brain Res 1994, 642: 281-9.
74. 3H]ketansenn binding in the human brain postmortem: Effect of suicide. Brain Res 1990, 507: 208-15.
75. 2 receptors and suicide. Lancet 1983, ii: 1256.
76. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991, 48: 355-63.
77. 3 receptors in schizophrenia: A postmortem study of the amygdala. Brain Res 1993, 616: 53-7.
78. 1 recognition sites. J Rec Res 1988, 8: 59-81.
79. Hamik, A., Peroutka, S.J. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989, 25: 569-75.
80. Kahn, R.S., Wetzler, S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991, 30: 1139-66.
81. 1C receptors. J Pharmacol Exp Ther 1987, 242: 552-7.
82. Wolf, W.A., Kuhn, D.M. The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem Int 1991, 19: 39-44.
83. Seibyl, J.P., Krystal, J.H., Price, L.H. et al. Effects of ritanserin on the behavioral, neuroendocrine and cardiovascular response to m-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991, 38: 227-36.
84. Iqbal, N., Asnis, G.M., Wetzler, S., Kahn, R.S., Kay, S.R., van Praag, H.M. The mCPP challenge test in schizophrenia: Hormonal and behavioral responses. Biol Psychiatry 1991, 30: 770-8.
85. Krystal, J.H., Seibyl, J.P., Price, L.H. et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993, 50: 624-35.
86. Kahn, R.S., Siever, L.J., Gabriel, S. et al. Serotonin function in schizophrenia: Effects of metachlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res 1992, 43: 1-12.
87. Lieberman, J.A., Kane, J.M., Alvir, J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987, 91: 415-33.
88. Wurtman, R.J., Heft, F., Melamed, E. Precursor control of neurotransmitter synthesis. Pharmacol Rev 1981, 32: 315-35.
89. Lauer, J., Inskip, W., Bemshon, J., Zeller, E. Observations on schizophrenic patients after iproniazid and tryptophan. Arch Neurol Psychiat 1958, 80: 122.
90. Pollin, W., Cardon, P.V., Kety, S.S. Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 1961, 133: 104-5.
91. Bowers, M.B.J. Cerebrospinal fluid5-hydroxyindoles and behavior after L-tryptophan and pyridoxine administration to psychiatric patients. Neuropharmacology 1970, 9: 599-604.
92. Morand, C., Young, S., Ervin, F. Clinical response of aggressive schizophrenics to oral tryptophan. Biol Psychiatry 1983, 18: 575-8.
93. Wyatt, R.J., Vaughan, T., Galanter, M., Kaplan, J., Green, J. Behavioral changes of chronic schizophrenic patients given L-5-hydroxytryptophan. Science 1972, 177: 1124-6.
94. Bigelow, L., Walls, P., Gillin, J., Wyatt, R. Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients. Biol Psychiatry 1979, 14: 53-67.
95. van Praag, H.M., Lemus, C., Kahn, R. Hormonal probes of central serotonergic activity: Do they really exist? Biol Psychiatry 1987, 22: 86-98.
96. Casacchia, M., Casati, C., Fazio, C. p-Chlorophenylalanine in schizophrenia. Biol Psychiatry 1975, 10: 109-10.
97. DeLisi, L., Freed, W., Gillin, J., Kleinman, J., Bigelow, L., Wyatt, R. p-Chlorophenylalanine trials in schizophrenic patients. Biol Psychiatry 1982, 11: 635-47.
98. Shore, D., Korpi, E.R., Bigelow, L.B., Zec, R.F., Wyatt, R.J. Fenfluramine and chronic schizophrenia. Biol Psychiatry 1985, 20: 329-52.
99. Stahl, S.M., Uhr, S.B., Berger, P.A. Pilotstudy on the effects of fenfluramine on negative symptoms in twelve schizophrenic patients. Biol Psychiatry 1985, 20: 1098-102.
100. Soper, H.V., Elliott, R.O., Rejzer, A.A., Marshall, B.D. Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenia patients. J Clin Psychopharmacol 1990, 10: 168-75.
101. Seeman, P., Lee, T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188: 1217-9.
102. Creese, I., Burt, D.R., Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 19: 481-3.
103. Peroutka, S.J., Snyder, S.S. Relationship of neuroleptic drugs effects at brain dopamine, serotonin, a-adrenergic and histamine receptors to clinical potency. Amer J Psychiatry 1980, 137: 1518-22.
104. Baldessarini, R.J., Frankenburg, F.R. Clozapine: A novel antipsychotic agent. New Engl J Med 1991, 324: 746-54.
105. Deutch, A., Moghadam, B., Innis, R. et al. Mechanisms of action of atypical antipsychotic drugs. Implication for novel therapeutic strategies for schizophrenia. Schizophrenia Res 1991, 4: 121-56.
106. Lieberman, J.A. Understanding the mechanism of action of atypical antipsychotic drugs. Brit J Psychiatry 1993, 163: 7-18.
107. 4. Neuropsychopharmacology 1992, 7: 261-84.
108. 1C sites. Eur J Pharmacol 1990, 191: 93-6.
109. Meltzer, H., Matsubara, S. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin-2 pK, values. J Pharmacol Exp Ther 1989, 251: 238-46.
110. Meco, G., Bedini, L., Bonifati, V., Sonsini, U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther Res 1989, 46: 876-904.
111. Mesotten, F., Suy, E., Pietquin, M., Burton, P., Heylen, S., Gelders, S. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 1989, 99: 445-9.
112. Claus, A., Bollen, J., DeCuyper, H. et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiat Scand 1992, 85: 295-305.
113. Hoyberg, O.J., Fensbo, C., Remvig, J., Lingjaerde, O., Sloth-Nielsen, M., Salvesen, I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiat Scand 1993, 88: 395-402.
114. Gelders, Y.G. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Brit J Psychiatry 1989, 155: 33-6.
115. 2 antagonist ritanserin in neuroleptic induced parkinsonism: A double blind comparison with orphenedrine and placebo. Clin Neuropharmacol 1990, 13: 500-6.
116. 2 antagonist ritanserin. Psychopharmacol Bull 1990, 26: 373-6.
117. Bleekers, E., Goldfarb, J., Green, J.P. Ritanserin in the treatment of negative symptoms in chronic schizophrenic patients. CINP (Kyoto, Japan) 1990.
118. Wiesel, F.A., Nordstrom, A.L., Farde, L., Eriksson, B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 1994, 114: 31-8.
119. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993, 266: 684-91.
120. Rossum, V. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966, 160: 492-4.
121. Carlsson, A., Lindqvisi, M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963, 20: 140-4.
122. Snyder, S.H. Amphetamine psychosis: A "model" schizophrenia mediated by catecholamines. Amer J Psychiatry 1973, 130: 61-7.
123. Angrist, B., van Kammen, D.P. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci 1984, 7: 388-90.
124. Hornykiewicz, O. Dopamine deficiency and dopamine substitution in Parkinson's disease. In: The Neurobiology of Dopamine Systems. Winlow, W., Markstein, R. (Eds.). Manchester University Press: Manchester 1986, 312-28.
125. Stevens, J. An anatomy of schizophrenia? Arch Gen Psychiatry 1973, 29: 177-89.
126. Kostowski, W., Giacalone, E., Garattini, S., Valzelli, L. Studies on behavioural and biochemical changes in rats after lesion of midbrain raphe. Eur J Pharmacol 1968, 4: 371-6.
127. Fibiger, H.C., Campbell, B.A. The effect of parachlorophenylalanine on spontaneous locomotor activity in the rat Neuropharmacology 1971, 10: 25-32.
128. Mabry, P., Campbell, B. Serotonergicinhibition of catecholamine-induced behavioral arousal. Brain Res 1973, 49: 381-91.
129. Neill, D., Grant, L.D., Grossman, S.P. Selective potentiation of locomotor effects on amphetamine by midbrain raphe lesion. Physiol Behav 1972, 9: 655-7.
130. Lucki, I., Harvey, J.A. Increased sensitivity to d-and l-amphetamine action after midbrain raphe lesions as measured by locomotor activity. Neuropharmacology 1979, 18: 243-9.
131. Costall, B., Naylor, R.J. Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphe nuclei. Eur J Pharmacol 1974, 29: 206-22.
132. Green, T.K., Harvey, J.A. Enhancement of amphetamine action after interruption of ascending serotonergic pathways. J Pharmacol Exp Ther 1974, 190: 109-17.
133. Segal, D. Differential effects of para-chlorophenylalanine on amphetamine-induced locomotion and stereotypy. Brain Res 1976, 116: 267-76.
134. Breese, G.R., Cooper, B.R., Mueller, R.A. Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine. Brit J Pharmacol 1974, 52: 307-14.
135. Hollister, A., Breese, G., Moreton Kuhn, C., Cooper, B., Schanberg, S. An inhibitory role for brain serotonin-containing systems in the locomotor effects of d-amphetamine. J Pharmacol Exp Ther 1976, 198: 12-22.
136. Costall, B., Naylor, R., Marsden, C., Pycock, C. Serotoninergic modulation of the dopamine response from the nucleus accumbens. J Pharm Pharmacol 1976, 28: 523-6.
137. Fink, H., Oelssner, W. LSD, mescaline and serotonin injected into medial raphe nucleus potentiate apomorphine hypermotility. Eur J Pharmacol 1981, 75: 289-96.
138. Costall, B., Naylor, R.J., Marsden, C.D., Pycock, C.J. Circling behavior produced by assymetric medial raphe lesions in rats. J Pharm Pharmacol 1976, 28: 248-9.
139. Giambalvo, C.T., Snodgrass, S.T. Biochemical and behavioral effects of serotonin neurotoxins on the nigra-striatal dopamine system: Comparison of injection sites. Brain Res 1978, 152: 555-66.
140. James, T.A., Starr, M.S. Rotational behaviour elicited by 5-HT in the rat: Evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. J Pharm Pharmacol 1980, 32: 196-200.
141. Nicolaou, N., García-Muñoz, M., Arbuthnott, G., Eccleston, D. Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei. Eur J Pharmacol 1979, 57: 295-305.
142. Tanner, T. Circling behaviour in the rat following unilateral injections of p-chlorophenylalanine and ethanolamine-O-sulphate into the substantia nigra. J Pharm Pharmacol 1978, 30: 158-61.
143. Blackburn, T.P., Cox, B., Heapy, C.G., Lee, T.F., Middlemiss, D.N. Supersensttivity of nigral serotonin receptor and rat rotational behavior. Eur J Pharmacol 1981, 71: 343-6.
144. De Simoni, M.G., Dal Toso, G., Sokola, A., Algeri, S. Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 1987, 411: 81-8.
145. Carter, C.J., Pycock, C.J. Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Brit J Pharmacol 1977, 60: 267P.
146. Waldmeier, P., Delini-Stula, A. Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979, 55: 363-73.
147. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 1989, 98: 45-50.
148. Grace, A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41: 1-24.
149. Svensson, T.H., Tung, C.S. Local cooling of prefrontal cortex induces pace-maker-like firing of dopamine neurons in rat ventral tegumental area in vivo. Acta Physiol Scand 1989, 136: 135-6.
150. Allen, R.M., Young, S.J. Phencyclidine-induced psychosis. Amer J Psychiatry 1978, 135: 1081-4.
151. Snyder, S.H. Phencyclidine. Nature 1980, 285: 355-6.
152. 2 receptor antagonism. Schizophrenia Res 1993, 11: 115P.
153. 2 antagonist ritanserin blocks the effect of prefrontal cortex inactivation on rat A10 dopamine neurons in vivo. Acta Physiol Scand 1989, 136: 497-8.
154. Grenhoff, J., Tung, C.S., Ugedo, L., Svensson, T.H. Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 1990, Suppl. 1: 29-33.
155. Chiodo, L., Bunney, B. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983, 3: 1607-19.
156. White, F.J., Wang, R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983, 1054-7.
157. Goldstein, J.M., Litwin, L.C., Sutton, E.B., Malick, J.B. Effects of ICI 169,369, a selective serotonin-2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 1989, 249: 673-80.
158. 2 receptors: Distribution, pharmacological characterization and region-specific regulation by clozapine. J Pharmacol Exp Ther 1992, 261: 1282-90.
159. 2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 1990, 253: 1162-70.
160. Nash, J.F. Ketanserin pretreatment attenuates MDMA-Induced dopamine release in the striaturn as measured by vivo microdialysis. Life Sci 1990, 47: 2401-8.
161. Schmidt, C.J., Sullivan, C.K., Fadayel, G.M. Blockade of striatal 5-hydroxytryptamine(2) receptors reduces the increase in extracellular concentrations of dopamine produced by the Amphetamine analogue 3.4-methylenedioxy-methamphetamine. J Neurochem 1994, 62: 1382-9.
162. 2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol 1993, 8: 25-32.
163. 2 receptors in interneurons. Synapse 1991, 9: 208-18.
164. Gellman, R.L., Aghajanian, G.K. Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res 1993, 600: 63-73.
165. Marek, G.J., Aghajanian, G.K. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: Blockade by MDL 100,907, a highly selective 5-HT(2A) receptor antagonist Eur J Pharmacol 1994, 259: 137-41.
166. 2 receptors in the rat brain: Neurochemical identification of cell types by immunocytochemistry. Neuropsychopharmacology 1994, 11: 157-66.
167. Benes, F.M., McSparren, J., Bird, E.D., Vincent, S.L., San Giovanni, J.P. Deficits in small interneurons in schizophrenic cortex. Arch Gen Psychiatry 1991, 48: 996-1001.
168. Selemon, L.D., Rajkowska, G., Goldman-Rakic, P.S. Cytologic abnormalities in area 9 of the schizophrenic cortex. Soc Neurosci Abstr 1993, 19: 200.
169. Pakkenberg, B. Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors. Biol Psychiatry 1993, 34: 768-72.
170. Akbarian, S., Kim, J.J., Potkin, S.G. et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995, 52: 258-66.
171. Arnold, S.E., Lee, V.M., Gur, R.E., Trojanowski, J.Q. Abnormal expression of two microtubule associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci USA 1991, 88: 10850-4.
172. Whitaker-Azmitia, P.M., Borella, A., Raio, N. Serotonin depletion in the adult rat causes loss of the dendritic marker MAP-2. A new animal model of schizophrenia? Neuropsychopharmacology 1995, 12: 269-72.
173. van Kammen, D.P., Murphy, D.L. Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia (Berl) 1975, 44: 215-24.
174. Grace, A.A. Cortical regulation of subcortical systems and its possible relevance to schizophrenia. J Neural Transm 1993, 91: 111-34.